Financial Performance: Phreesia, Inc. reported a net income of $4.27 million for Q3 of fiscal 2026, a turnaround from a net loss of $14.40 million in the same quarter last year, with total revenue increasing by 13% to $120.33 million.
Guidance Adjustments: The company adjusted its fiscal year 2026 revenue guidance, lowering the low end to $479 million and raising the high end to $481 million, while also increasing its Adjusted EBITDA outlook to $99 million to $101 million.
Future Projections: For fiscal year 2027, Phreesia anticipates revenue between $545 million and $559 million, with an Adjusted EBITDA forecast of $125 million to $135 million, alongside expected growth in healthcare services.
Stock Performance: Phreesia's stock closed at $20.12, reflecting a decrease of 0.84% on the previous trading day.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PHR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is 29.09 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is 29.09 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.660
Low
24.00
Averages
29.09
High
35.00
Current: 14.660
Low
24.00
Averages
29.09
High
35.00
DA Davidson
Buy
downgrade
$35 -> $30
2026-01-23
Reason
DA Davidson
Price Target
$35 -> $30
AI Analysis
2026-01-23
downgrade
Buy
Reason
DA Davidson lowered the firm's price target on Phreesia to $30 from $35 and keeps a Buy rating on the shares. The firm had a discussion with the company regarding the underlying long-term growth drivers with the potential to produce upside to the 8%-10% organic Y/Y revenue growth guide for FY27 and positive revisions to out-year numbers, and it has come away with a constructive view on the FY27 setup, noting that the recent stock price underperformance is a buying opportunity, the analyst tells investors in a research note.
RBC Capital
Ryan Halsted
resume
$26
2026-01-09
Reason
RBC Capital
Ryan Halsted
Price Target
$26
2026-01-09
resume
Reason
RBC Capital analyst Ryan Halsted resumed coverage of Phreesia with an Outperform rating and $26 price target. Phreesia is positioned to accelerate growth and reach target margins following its pivot to profitability, leveraging its patient intake platform across 4,400 physicians to monetize network breadth and capture healthcare utilization economics, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHR
Unlock Now
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Barron’s Stock Selections Outperform the Market in 2025: Insights on Our Successes and Missteps.
1 day agoBarron's
Market Volatility: A little chaos in the market can create opportunities for stock-picking, allowing investors to identify undervalued stocks.
Investment Strategy: Embracing market fluctuations can lead to better investment decisions, as it encourages a more active approach to stock selection.
Continue Reading
Phreesia Shares Have Plummeted, But We Maintain Our Recommendation.
Dec 22 2025Barron's
Stock Performance: Some stocks are performing well, while others are struggling, highlighting a mixed market environment.
Phreesia's Status: Phreesia is mentioned as a stock that does not fit neatly into the categories of hot or cold, suggesting a unique position in the market.
Continue Reading
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?
How does the company's performance compare to its main competitors in the same sector?
